Focused On-demand Library for DNA-directed RNA polymerase, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O00411

UPID:

RPOM_HUMAN

Alternative names:

Alternative UPACC:

O00411; O60370

Background:

The DNA-directed RNA polymerase, mitochondrial, is pivotal in mitochondrial DNA transcription, converting it into RNA using ribonucleoside triphosphates. It forms part of the mitochondrial transcription initiation complex alongside TFB2M and TFAM, essential for mitochondrial DNA basal transcription. This complex facilitates promoter DNA opening and non-template strand trapping, with POLRMT also exhibiting DNA primase activity for lagging-strand DNA synthesis initiation.

Therapeutic significance:

Linked to Combined oxidative phosphorylation deficiency 55, a mitochondrial disorder affecting development and muscle function, understanding the role of DNA-directed RNA polymerase, mitochondrial, could open doors to potential therapeutic strategies.